JMP Securities highlights Imcivree’s role in Rhythm Pharmaceuticals stock outlook By Investing.com

On Tuesday, Rhythm Pharmaceuticals (NASDAQ:) stock received a positive assessment from JMP Securities as the firm initiated coverage with a Market Outperform rating and a price target set at $64.00.

The biopharmaceutical company, recognized for its leadership in MC4R biology, focuses on developing treatments for patients with rare genetic disorders causing incessant hunger and obesity—conditions not effectively addressed by other anti-obesity drugs.

Rhythm’s primary drug, setmelanotide, operates as a melanocortin-4 receptor (MC4R) agonist and was first authorized in the United States in 2020 under the brand name Imcivree.

It is prescribed for chronic weight management in individuals who have obesity due to certain genetic mutations affecting MC4R pathways. The drug’s approval was extended in 2022 and has also gained approval in the European Union.

Imcivree has shown significant commercial success, with sales reaching $77 million in 2023 and a 79% year-over-year increase to $55 million in the first half of 2024.

The analyst highlighted that glucagon-like peptide (GLP)- based drugs do not provide a solution for the functional impairments caused by these genetic mutations, which is why such medications exhibit little to no efficacy for the targeted patient population. In contrast, Imcivree directly addresses the condition’s mechanistic differences, meeting a high unmet medical need.

The high efficacy and unique mechanism of Imcivree have led to its premium pricing, which is approximately $370,000 per year. This is in stark contrast to GLP drugs, which range from $12,000 to $16,000 annually. Payers, including state Medicaid programs in the U.S. and several European countries, have supported this pricing strategy.

Notably, even Germany, known for its stringent healthcare spending policies, particularly regarding lifestyle drugs like weight loss medications, has included Imcivree in its coverage.

In other recent news, Rhythm Pharmaceuticals has seen several developments. The U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) to extend treatment to younger children with certain genetic obesity disorders.

The FDA set a goal date of December 26, 2024, to review the application under Priority Review status. The company also reported strong Q2 2024 results, with earnings reaching $29.1 million, primarily driven by the sales of IMCIVREE.

Canaccord Genuity adjusted its financial outlook for Rhythm Pharmaceuticals, lowering the price target to $77 from $79 but maintaining a Buy rating on the stock.

This followed the company’s Q2 results, which aligned with consensus expectations. Rhythm Pharmaceuticals has also initiated Phase 2 trials for two new MC4R agonists, expanding their development pipeline.

The company is also progressing with its Phase 3 study of setmelanotide in patients with hypothalamic obesity. This trial aims to detect a 10% difference versus placebo in the primary endpoint of Body Mass Index (BMI) reduction. These recent developments reflect Rhythm Pharmaceuticals’ commitment to growth and strategic approach to overcoming challenges.

InvestingPro Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) presents a compelling case for investors with a keen eye on the biopharmaceutical sector, especially given its specialization in rare genetic disorders of obesity. InvestingPro data underscores the company’s robust gross profit margin of 88.8% for the last twelve months as of Q2 2024, which aligns with the high efficacy and premium pricing strategy of its primary drug, Imcivree. Despite the company’s impressive revenue growth of 132.56% over the same period, analysts have raised concerns about profitability, with the company not expected to be profitable this year and operating with a negative earnings per share (EPS) of -$4.38.

Investors should note that Rhythm’s stock price has been quite volatile, but it has delivered a strong return over the last year, with a price total return of 98.8%. This volatility and performance may attract those looking for growth opportunities in their portfolios. However, the company is trading at a high Price / Book multiple of 76.95, which may suggest a premium market valuation that could be a point of consideration for value-focused investors. For those interested in a deeper dive, there are additional InvestingPro Tips available that provide further insights into Rhythm Pharmaceuticals’ financial health and market performance (https://www.investing.com/pro/RYTM).

With the market cap standing at $3.03 billion, Rhythm Pharmaceuticals is a mid-cap player in the biotech industry, which typically involves higher risk and potentially higher reward scenarios. The company’s liquid assets exceeding short-term obligations is a positive sign for its financial stability. For investors seeking more detailed analysis and tips, InvestingPro offers a comprehensive list, including 12 additional InvestingPro Tips that can help in making a more informed investment decision.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.